NCT06309966: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
- State
- Under way
- Phase
- Phase 2 and Phase 3
- People
- 390 planned
- Started
- 13 May 2024
- Primary completion
- Oct 2026
- Arms
- BHV-7000 50 mg, BHV-7000 75 mg
- Results
- None posted
- 13 Mar 2024: Trial registered
- 13 May 2024: Trial started